Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)‘s stock had its “buy” rating reissued by investment analysts at Maxim Group in a report released on Tuesday. They presently have a $23.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $21.00. Maxim Group’s price objective points to a potential upside of 114.95% from the company’s previous close.

A number of other research analysts also recently commented on SCMP. Jefferies Group LLC set a $13.00 price target on Sucampo Pharmaceuticals and gave the company a “hold” rating in a report on Thursday, April 20th. ValuEngine downgraded Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Zacks Investment Research raised Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 4th. TheStreet downgraded Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a report on Wednesday, August 2nd. Finally, Roth Capital set a $30.00 target price on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $17.63.

Sucampo Pharmaceuticals (NASDAQ:SCMP) traded up 2.39% during midday trading on Tuesday, reaching $10.70. The company had a trading volume of 627,562 shares. The firm’s market capitalization is $494.28 million. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $17.55. The firm’s 50-day moving average price is $10.65 and its 200 day moving average price is $10.72.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.06. The firm had revenue of $59.90 million during the quarter, compared to the consensus estimate of $56.44 million. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. Sucampo Pharmaceuticals’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.24 earnings per share. Equities analysts anticipate that Sucampo Pharmaceuticals will post $1.02 earnings per share for the current fiscal year.

WARNING: This piece was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/08/sucampo-pharmaceuticals-inc-nasdaqscmp-stock-rating-reaffirmed-by-maxim-group.html.

In other Sucampo Pharmaceuticals news, insider Jones W. Bryan bought 4,700 shares of the stock in a transaction that occurred on Friday, August 4th. The shares were purchased at an average cost of $10.60 per share, for a total transaction of $49,820.00. Following the transaction, the insider now directly owns 4,700 shares in the company, valued at $49,820. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.13% of the stock is owned by company insiders.

Several institutional investors have recently modified their holdings of the stock. Louisiana State Employees Retirement System boosted its position in shares of Sucampo Pharmaceuticals by 1.0% in the second quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 100 shares during the last quarter. Arizona State Retirement System boosted its position in shares of Sucampo Pharmaceuticals by 1.6% in the second quarter. Arizona State Retirement System now owns 13,100 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 200 shares during the last quarter. Capstone Asset Management Co. boosted its position in shares of Sucampo Pharmaceuticals by 2.1% in the second quarter. Capstone Asset Management Co. now owns 12,360 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 260 shares during the last quarter. Texas Permanent School Fund boosted its position in shares of Sucampo Pharmaceuticals by 2.2% in the second quarter. Texas Permanent School Fund now owns 18,319 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 398 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Sucampo Pharmaceuticals by 0.9% in the second quarter. Rhumbline Advisers now owns 48,810 shares of the biopharmaceutical company’s stock worth $513,000 after buying an additional 423 shares during the last quarter. Institutional investors own 58.20% of the company’s stock.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.